One-Year Results of Photodynamic Therapy Combined with Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration

Table 2

Recurrence rates of exudative changes after successful initial treatment.

Initial treatment	Eyes (%)	Recurrence eyes (%)
1 PDT + 2 ranibizumab	23 (60.5%)	1 (4.3%)
1 PDT + 3 ranibizumab	9 (23.7%)	2 (22.2%)
1 PDT + 4 ranibizumab	2 (5.3%)	1 (50.0%)
1 PDT + 5 ranibizumab	2 (5.3%)	0 (0.0%)
2 PDT + 6 ranibizumab	2 (5.3%)	0 (0.0%)
Total	38 eyes	4 eyes (10.5%)

PDT: photodynamic therapy.